An open-label, single-sequence pharmacokinetic study in healthy subjects to assess the potential of AEB071 to inhibit and induce CYP1A2 using caffeine as a probe substrate.

Trial Profile

An open-label, single-sequence pharmacokinetic study in healthy subjects to assess the potential of AEB071 to inhibit and induce CYP1A2 using caffeine as a probe substrate.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Sotrastaurin (Primary) ; Caffeine
  • Indications Liver transplant rejection; Psoriasis; Renal transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jan 2013 Status changed from recruiting to active, no longer recruiting, according to Clinical Trials Registry - India
    • 10 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top